Hamada Altalib
Neurology · West Haven, CTNPI 1073700548
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,000 of the $7,932 with a category attached, or 75.6%. Eisai Inc. accounts for 94.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $7,525 and has fallen 99.4% since, to $45 in 2025.
Across 15 payments — averaging $528.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$8K
- Greenwich Biosciences, Inc.$148
- Neurelis, Inc.$120
- UCB, Inc.$105
- Jazz Pharmaceuticals Inc.$33
Across 24 payments — averaging $9823.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$101K
- Pfizer$42K
- UCB SA$35K
- Mylan Specialty L.p.$30K
- UCB, Inc.$29K
What the payments were for
- Consulting fees$6,00076%
- Travel & lodging$1,31817%
- Food & beverage$6138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 10 | $7,525 |
| Greenwich Biosciences, Inc. | 1 | $148 |
| Neurelis, Inc. | 1 | $120 |
| UCB, Inc. | 2 | $105 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,932 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CarbatrolCarbamazepine | 12 | $5,794 |
| Clobazam | 25 | $5,073 |
| Lamotrigine | 59 | $733 |
| Lamotrigine ErLamotrigine | 11 | $679 |
| Gabapentin | 12 | $411 |
| Escitalopram Oxalate | 23 | $246 |
| Pregabalin | 11 | $117 |
| Clonazepam | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Other neurology in West Haven
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
- Peter GottschalkFairfield$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.